The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 23, Issue 6, 2005, Pages 795-800

  Cohen, G ^a   Courvoisier, N ^a   Cohen, J D ^a   Zaltni, S ^a   Sany, J ^a   Combe, Bernard ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Anti TNF therapy; Etanercept; Infliximab; Treatment switching

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

ADULT; AGED; ARTICLE; BRONCHITIS; COHORT ANALYSIS; CORRELATION ANALYSIS; CYTOLYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; NOCARDIOSIS; PLEURISY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 29944442627     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
2. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
3. MAINI R, St CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
4. LIPSKY PE, van der HEIJDE DM, St CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
5. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
6. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
7. KREMER JM, WEINBLATT ME, BANKHURST AD et al.: Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003; 48: 1493-9.
8. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
9. FLEISCHMANN RM: Examining the efficacy of biologic therapy: are there real differences? J Rheumatol 2002; 65 (Suppl): 27-32.
10. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
11. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
12. PREVOO ML, van 'T HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
13. van GESTEL AM, HAAGSMA CJ, van RIEL PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
14. van VOLLENHOVEN RF: Switching between biological agents. Clin Exp Rheumatol 2004; 22: S115-21.
15. BROCQ O, PLUBEL Y, BREUIL V: Etanercept-infliximab switch in rheumatoïd arthritis. Presse Med 2002; 31: 1836-9.
16. van VOLLENHOVEN R, HARJU A, BRANNEMARK S, KLARESKOG L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tomour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195-8.
17. ANG HT, HELGOTT S: Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003; 30: 2315-8.
18. SHERGY WJ, PHILLIPS Jr RM, HUNT RE, HERNANDEZ J: Safety and efficacy of infliximab therapy after etanercept failure: a case series. Arthritis Rheum 2001; 44 (Suppl): S81.
19. HANSEN KE, HILDEBRAND JP, GENOVESE M et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004; 31:1098-102.
20. GOMEZ-PUERTA JA, SANMARTI R, RODRIGUEZ-CROS JR, CANETE JD: Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004; 63: 896.